Modern Vascular Announces Hiring of Dr. Steve Berkowitz
Company's first full-time Chief Medical Officer is a renowned expert in process improvement, healthcare reform, and ensuring superior clinical outcomes PHOENIX, June 28, 2021 -- (Healthcare Sales & Marketing Network) -- Modern Vascular, a pioneering me... Devices, Interventional, Personnel Modern Vascular, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 28, 2021 Category: Pharmaceuticals Source Type: news

Janssen Submits New Drug Application to U.S. FDA for XARELTO ® (rivaroxaban) to Help Prevent and Treat Blood Clots in Pediatric Patients
RARITAN, NJ, June 23, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the use of XARELTO® (rivaroxaban) in pediatric patients. The NDA seeks two pediatric indications: treatment of venous thromboembolism (VTE, or blood clots) and reduction in the risk of recurrent VTE in patients aged birth to less than 18 years of age after at least five days of initial parenteral anticoagulant treatment; and thromboprophylaxis (prevention of blood clots) in patients aged 2 years and older with co...
Source: Johnson and Johnson - June 23, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Cagent Vascular receives $9M investment to accelerate marketing of its lead product
The FDA granted marketing clearance last year for the company's product used to treat below-the-knee peripheral artery disease. (Source: bizjournals.com Health Care:Pharmaceuticals headlines)
Source: bizjournals.com Health Care:Pharmaceuticals headlines - June 21, 2021 Category: Pharmaceuticals Authors: John George Source Type: news

Cagent Vascular receives $9M investment to accelerate marketing of its lead product
The FDA granted marketing clearance last year for the company's product used to treat below-the-knee peripheral artery disease. (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - June 21, 2021 Category: Biotechnology Authors: John George Source Type: news

Blood Lipid Control Inadequate in PAD Patients Blood Lipid Control Inadequate in PAD Patients
Lipid-lowering therapy remains underused and LDL-C is poorly controlled in many patients with peripheral artery disease, a new study shows.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 18, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

High'Remnant' Cholesterol Linked to Fivefold Increase in PAD High'Remnant' Cholesterol Linked to Fivefold Increase in PAD
High levels of remnant cholesterol were associated with an increased risk for peripheral artery disease of up to fivefold in a large Danish analysis, although questions remain over its current clinical utility.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - June 2, 2021 Category: Cardiology Tags: Cardiology News Source Type: news

Late-Breaking Data at ACC.21 Show XARELTO ® (rivaroxaban) Plus Aspirin Significantly Reduced Total Ischemic Events in Peripheral Artery Disease (PAD) Patients After Lower-Extremity Revascularization
RARITAN, N.J., May 16, 2021 – The Janssen Pharmaceutical Companies of Johnson & Johnson today presented new data from the Phase 3 VOYAGER PAD study which showed XARELTO® (rivaroxaban) (2.5 mg twice daily) in combination with aspirin (100 mg once daily) consistently reduced severe vascular events in patients with peripheral artery disease (PAD) after lower-extremity revascularization (LER) compared to aspirin alone regardless of whether it was the first, second, third, or subsequent event. The primary results of VOYAGER PAD showed that XARELTO® plus aspirin reduced first events by 15 percent among patients...
Source: Johnson and Johnson - May 16, 2021 Category: Pharmaceuticals Tags: Innovation Source Type: news

Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
Title: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery DiseaseCategory: Health NewsCreated: 4/9/2021 12:00:00 AMLast Editorial Review: 4/12/2021 12:00:00 AM (Source: MedicineNet Heart General)
Source: MedicineNet Heart General - April 12, 2021 Category: Cardiology Source Type: news

AHA News: Not Just Bad Shoes and Sore Muscles – She Had Peripheral Artery Disease
FRIDAY, April 9, 2021 (American Heart Association News) -- Abigail Dudek celebrated her 40th birthday in Las Vegas a few months ago, grateful to go hiking and cycling without pain for the first time in more than two years. The problem started in... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 9, 2021 Category: General Medicine Source Type: news

For People With PAD, Exercise Can Be Tough But Rewarding
WEDNESDAY, April 7, 2021 -- Fast-paced walking is painful for the millions of people with peripheral artery disease (PAD). But new research shows that a slower, pain-free pace won't cut it if improvement in mobility is the goal. The study included... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 7, 2021 Category: General Medicine Source Type: news

No pain, no gain in exercise for peripheral artery disease
(Northwestern University) No pain means no gain when it comes to reaping exercise benefits for people with peripheral artery disease, reports a new study. In people with peripheral artery disease, walking for exercise at an intensity that induces ischemic leg pain (caused by restricted blood flow) improves walking performance -- distance and length of time walking -- the study found. Walking at a slow pace that does not induce ischemic leg symptoms is no more effective than no exercise at all, the study showed. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 6, 2021 Category: International Medicine & Public Health Source Type: news

High cholesterol symptoms: Three serious warning signs in your feet - what to look for
HIGH cholesterol levels can lead to heart attacks and strokes but a lesser-known but equally serious complication is peripheral artery disease . There are three telltale signs in your feet that consistently high cholesterol levels have caused PAD to develop. (Source: Daily Express - Health)
Source: Daily Express - Health - April 6, 2021 Category: Consumer Health News Source Type: news

Cochrane International Mobility - Carolina Severiche Mena
Cochrane is made up of  11,000 members and over 67,000 supporters come from more than 130 countries, worldwide. Our volunteers and contributors are researchers, health professionals, patients, carers, people passionate about improving health outcomes for everyone, everywhere.Getting involved in Cochrane ’s work means becoming part of a global community. TheCochrane International Mobility programme connects successful applicants with a placement in a host Cochrane Group, learning more about the production, use, and knowledge translation of Cochrane reviews. The prgramme offers opportunities fo...
Source: Cochrane News and Events - March 3, 2021 Category: Information Technology Authors: Lydia Parsonson Source Type: news

UTA researcher examining potentially less invasive treatment for peripheral artery disease
(University of Texas at Arlington) A University of Texas at Arlington bioengineer is designing a nanoparticle delivery system that will take needed plasmids to arteries in patients who are suffering from peripheral artery disease (PAD) in their arms and legs. (Source: EurekAlert! - Biology)
Source: EurekAlert! - Biology - March 3, 2021 Category: Biology Source Type: news

Johnson & Johnson Reports 2020 Fourth-Quarter and Full Year Results
New Brunswick, N.J. (January 26, 2021) – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2020. “Our notable full year performance reflects the continued confidence from patients, physicians, customers and consumers in our life-enhancing products and medicines, particularly throughout the COVID-19 pandemic,” said Alex Gorsky, Chairman and Chief Executive Officer. “I’m incredibly proud of our Johnson & Johnson teams around the world for going above and beyond to meet stakeholder needs. These efforts, and our commitment to families around the world a...
Source: Johnson and Johnson - January 26, 2021 Category: Pharmaceuticals Tags: Our Company Source Type: news

Intradialytic Hypotension Tied to Peripheral Artery Disease
TUESDAY, Jan. 5, 2021 -- More frequent intradialytic hypotension (IDH) during hemodialysis is associated with a higher incidence of subsequent peripheral artery disease (PAD) diagnosis, according to a study published online Dec. 11 in the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - January 5, 2021 Category: Pharmaceuticals Source Type: news

Deaths Not Up With Paclitaxel-Coated Devices in PAD
THURSDAY, Dec. 17, 2020 -- For endovascular treatment of peripheral artery disease, paclitaxel-coated devices do not result in higher mortality than uncoated devices, according to a study published online Dec. 9 in the New England Journal of... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - December 17, 2020 Category: Pharmaceuticals Source Type: news

Statins can save lives, are they being used?
(Mayo Clinic) People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - December 1, 2020 Category: International Medicine & Public Health Source Type: news

Statins can save lives, are they being used?
ROCHESTER, Minn. ? People who have coronary artery disease, stroke or peripheral artery disease often are prescribed a statin, a cholesterol-lowering drug that reduces the risk of heart attack or stroke. In a recent publication in JAMA Network Open, Mayo Clinic researchers identify trends in statin use across the U.S. among people with these diseases, [...] (Source: News from Mayo Clinic)
Source: News from Mayo Clinic - December 1, 2020 Category: Databases & Libraries Source Type: news

Rivaroxaban to Prevent Brain Infarcts and Cognitive Decline Rivaroxaban to Prevent Brain Infarcts and Cognitive Decline
Might rivaroxaban with or without aspirin significantly reduce the rate of covert infarct over aspirin alone among patients with stable coronary and peripheral vascular disease?Stroke (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 25, 2020 Category: Consumer Health News Tags: Neurology & Neurosurgery Journal Article Source Type: news

New XARELTO ® (rivaroxaban) Peripheral Artery Disease (PAD) Data from EXPLORER Clinical Research Program to be Unveiled at American Heart Association (AHA) Scientific Sessions 2020
RARITAN, N.J., November 9, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced that 10 data presentations will be shared at the virtual American Heart Association (AHA) Scientific Sessions 2020 from November 13-17. Most notably, four new sub-analyses of XARELTO® (rivaroxaban) from the landmark VOYAGER PAD trial, part of the EXPLORER global cardiovascular research program, will be presented, including two live, featured science oral presentations. “We're pleased VOYAGER PAD was selected to be front and center once again at a major medical congress, as there's an urgent need f...
Source: Johnson and Johnson - November 9, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

The world's largest RCT investigating use of MagicTouch PTA Sirolimus Coated balloon for peripheral artery disease kicks off to a flying start
ZÜRICH, Nov. 9, 2020 -- (Healthcare Sales & Marketing Network) -- Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the SirPAD (Sirolimus in Peripheral Artery Disease) tr... Devices, Interventional Concept Medical, critical limb ischemia, SirPAD , MagicTouch PTA, sirolimus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 9, 2020 Category: Pharmaceuticals Source Type: news

FDA Okays Ranger Drug-Coated Balloon for PAD FDA Okays Ranger Drug-Coated Balloon for PAD
The approval offers a tailwind for a field still coming to terms with safety concerns regarding the use of DCB in peripheral artery disease.FDA Approvals (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - November 4, 2020 Category: Cardiology Tags: Cardiology News Alert Source Type: news

Boston Scientific Receives FDA Approval for the Ranger(TM) Drug-Coated Balloon
Company provides physicians with first portfolio comprised of drug-eluting stent and drug-coated balloon for the treatment of patients with peripheral artery disease MARLBOROUGH, Mass., Nov. 2, 2020 -- (Healthcare Sales & Marketing Network) -- Boston S... Devices, Interventional, FDA, Product Launch Boston Scientific, Ranger, Drug-Coated Balloon, peripheral artery disease (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - November 2, 2020 Category: Pharmaceuticals Source Type: news

Janssen Submits Application to U.S. FDA for New Indication to Expand Use of XARELTO ® (rivaroxaban) in Patients with Peripheral Artery Disease
RARITAN, NJ, October 26, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today it has submitted a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for a new indication to expand the use of XARELTO® (rivaroxaban) in patients with peripheral artery disease (PAD). If approved, this new indication for the XARELTO® vascular dose (2.5 mg twice daily plus aspirin 75-100 mg once daily) would include reducing the risk of major thrombotic vascular events such as heart attack, stroke and amputation in patients after recent lower-extremity revasculariz...
Source: Johnson and Johnson - October 26, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news

Rivaroxaban-application-submitted-US-FDA-indication-patients-after-lower-extremity-revascularization
FDA submission based on results from Phase III VOYAGER PAD study which showed a significant reduction in the primary efficacy endpoint in patients after lower-extremity revascularization due to symptomatic peripheral artery disease (PAD) / There is currently no Class I Guideline recommended treatment for this patient population / It is estimated that as many as 20 million Americans are living with PAD (Source: Bayer Company News)
Source: Bayer Company News - October 26, 2020 Category: Pharmaceuticals Source Type: news

Paclitaxel-Coated Devices Don't Increase Mortality Paclitaxel-Coated Devices Don't Increase Mortality
New results from VOYAGER PAD showing no suggestion of increased mortality may finally put to rest questions about the safety of paclitaxel devices in peripheral artery disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - October 21, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Depression Affects Recovery in Peripheral Artery Disease Depression Affects Recovery in Peripheral Artery Disease
As with other disorders, rates of depression are higher among female patients with peripheral artery disease compared to their male counterparts.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - September 1, 2020 Category: Cardiology Tags: Psychiatry News Source Type: news

Enrolment initiated in World's First RCT with Sirolimus Coated Balloon for the treatment of Below-the-Knee (BTK) Peripheral Artery Disease
SINGAPORE, Aug. 27, 2020 -- (Healthcare Sales & Marketing Network) -- Concept Medical Inc., focused on vascular intervention drug delivery devices, has announced the enrolment of the first patient in the FUTURE BTK trial (Randomized Controlled Trial of Fi... Devices, Interventional Concept Medical, critical limb ischemia, angioplasty, MagicTouch PTA, sirolimus (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - August 27, 2020 Category: Pharmaceuticals Source Type: news

FDA Drug Safety Communication: FDA confirms increased risk of leg and foot amputations with the diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR)
Based on new data from two large clinical trials, FDA has concluded that the type 2 diabetes medicine canagliflozin (Invokana, Invokamet, Invokamet XR) causes an increased risk of leg and foot amputations. We are requiring new warnings, including our most prominent Boxed Warning, to be added to the canagliflozin drug labels to describe this risk. Patients taking canagliflozin should notify your health care professionals right away if you develop new pain or tenderness, sores or ulcers, or infections in your legs or feet. Talk to your healthcare professional if you have questions or concerns. Do not stop taking your diabete...
Source: FDA Center for Drug Evaluation and Research - What's New - August 26, 2020 Category: Drugs & Pharmacology Authors: FDA Source Type: news

Depression May Hinder Recovery From Narrowed Arteries
MONDAY, Aug. 17, 2020 -- People with peripheral artery disease (PAD) and depression have worse recovery than those who aren't depressed, a new study finds. That's especially true for women, the researchers said. " This is the first study to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - August 17, 2020 Category: General Medicine Source Type: news

Women Have More Depression With Peripheral Artery Disease
Depressive symptoms associated with worse disease - specific health status (Source: The Doctors Lounge - Psychiatry)
Source: The Doctors Lounge - Psychiatry - August 13, 2020 Category: Psychiatry Tags: Cardiology, Family Medicine, Geriatrics, Gynecology, Internal Medicine, Psychiatry, Surgery, Anesthesiology & amp; Pain, Journal, Source Type: news

Women Have More Depression With Peripheral Artery Disease
THURSDAY, Aug. 13, 2020 -- Women with peripheral artery disease (PAD) have a higher burden of depressive symptoms compared with men, according to a study published online Aug. 12 in the Journal of the American Hospital Association. Qurat-ul-ain... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - August 13, 2020 Category: Pharmaceuticals Source Type: news

University of Edinburgh seeks - Research Fellow
The Usher Institute at the University of Edinburgh is seeking a highly skilled and motivated epidemiologist/research fellow to work in the field of vascular disease, including both the diagnosis and treatment of peripheral vascular diseases and the development of vascular complications of type 2 diabetes. The primary role will be to undertake a series of high quality systematic reviews on the prevention, diagnosis and treatment of vascular diseases, including abdominal aortic aneurysm, venous thromboembolism and peripheral arterial disease, within the core programme of work which constitutes the CSO funded research project...
Source: Cochrane News and Events - July 22, 2020 Category: Information Technology Authors: Lydia Parsonson Source Type: news

The Prevention of Cardiovascular Disease in Older Adults The Prevention of Cardiovascular Disease in Older Adults
This review summarizes evidence regarding the prevention of three common CVDs in older adults, with a focus on those over 75: stroke, coronary artery disease, and peripheral artery disease.Journal of the American Geriatrics Society (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 17, 2020 Category: Consumer Health News Tags: Internal Medicine Journal Article Source Type: news

Statin, Aspirin Uptake Low With Peripheral Artery Disease, Stroke
MONDAY, May 18, 2020 -- Uptake of guideline-directed preventive therapies is lower for patients with stroke and peripheral artery disease (PAD) compared with those with coronary artery disease (CAD), according to a study presented at the American... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 18, 2020 Category: Pharmaceuticals Source Type: news

Researchers suggest hot water therapy could be as effective as exercise for people with peripheral artery disease
(Natural News) Hot water therapy can improve functional ability and cardiovascular health in individuals with peripheral artery disease (PAD), according to a recent study published in the American Journal of Physiology-Heart and Circulatory Physiology. A team of researchers from New Zealand found evidence indicating that heat therapy via hot-water immersion yields the same health benefits as... (Source: NaturalNews.com)
Source: NaturalNews.com - May 13, 2020 Category: Consumer Health News Source Type: news

Micro Medical Solutions: First Case Completed in STAND Study, the Pivotal Clinical Trial of MicroStent
Major milestone reached in journey toward FDA approval for potentially limb-saving treatment of peripheral artery disease WILMINGTON, Mass., May 12, 2020 -- (Healthcare Sales & Marketing Network) -- Micro Medical Solutions (MMS) today announced the fir... Devices, Interventional Micro Medical Solutions, MicroStent, vascular stent, limb salvage (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - May 12, 2020 Category: Pharmaceuticals Source Type: news

Heavy Drinking Tied to Raised Stroke Risk, Study Finds
TUESDAY, May 5, 2020 -- Lots of boozing might increase your risk for a stroke, Swedish researchers report. Heavy alcohol use can triple your risk for peripheral artery disease, a narrowing of arteries that results in reduced blood flow, usually to... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - May 5, 2020 Category: General Medicine Source Type: news

High Alcohol Consumption May Be Causally Tied to Stroke, PAD
TUESDAY, May 5, 2020 -- Higher alcohol consumption may be causally associated with an increased risk for stroke and peripheral artery disease, according to a study published online May 5 in Circulation: Genomic and Precision Medicine. Susanna C.... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 5, 2020 Category: Pharmaceuticals Source Type: news

Genetic study ties higher alcohol consumption to increased stroke and PAD risk
(American Heart Association) Using genetic analysis, researchers found higher alcohol consumption increased risks for stroke and peripheral artery disease (PAD).Studies using genetic analysis don't rely on observational data, which often use self-reported data and could be subject to unreported risk factors. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - May 5, 2020 Category: International Medicine & Public Health Source Type: news

Work Stress May Raise the Risk for Peripheral Artery Disease Work Stress May Raise the Risk for Peripheral Artery Disease
People with very demanding jobs but little control are more likely to be hospitalized with peripheral artery disease than those with less work-related stress, a new study finds.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 30, 2020 Category: Consumer Health News Tags: Cardiology News Source Type: news

Job Strain Linked to Increase in Risk for PAD Hospitalization
TUESDAY, April 28, 2020 -- Job strain is associated with a 1.41-fold increase in the average risk for peripheral artery disease (PAD) hospitalization, according to a study published online April 28 in the Journal of the American Heart... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - April 28, 2020 Category: Pharmaceuticals Source Type: news

Job Strain May Boost Odds of Serious Artery Disease
TUESDAY, April 28, 2020 -- Work stress may increase your risk for ending up in the hospital with peripheral artery disease, a new study suggests. Peripheral artery disease (PAD) occurs when cholesterol or other fatty substances accumulate in blood... (Source: Drugs.com - Daily MedNews)
Source: Drugs.com - Daily MedNews - April 28, 2020 Category: General Medicine Source Type: news

On-the-job stress raises risk for peripheral artery disease, study finds
Stress on the job may increase a person's risk for peripheral artery disease, according a study published Tuesday in the Journal of the American Heart Association. (Source: Health News - UPI.com)
Source: Health News - UPI.com - April 28, 2020 Category: Consumer Health News Source Type: news

Johnson & Johnson Reports 2020 First-Quarter Results:
New Brunswick, N.J. (April 14, 2020) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2020. The Company also announced earlier today that its Board of Directors declared a 6.3% increase in the quarterly dividend rate, from $0.95 per share to $1.01 per share. At the new rate, the indicated dividend on an annual basis is $4.04 per share compared to the previous rate of $3.80 per share. “With Johnson & Johnson’s century-plus history of leading in times of great challenge, we are mobilizing our resources across the Company in the fight against the COVID-19 pandemic,” sai...
Source: Johnson and Johnson - April 14, 2020 Category: Pharmaceuticals Tags: Our Company Source Type: news

COVID-19 Business Updates Provide Some Clarity
The unknowns still outnumber the knowns, but recent business updates provide some clarity around how the medical device industry is fairing during the COVID-19 pandemic. First and foremost, it is clear that companies are hurting in the areas of elective procedures, which are being deferred. But there may be some silver linings hidden amongst the bad news. Needham & Co. medtech analyst Mike Matson estimates that medical device sales across the industry will continue to drop by an average of 40% to 50% until the economy begins to reopen and hospitals start to resume elective procedures. Matson's e...
Source: MDDI - April 10, 2020 Category: Medical Devices Authors: Amanda Pedersen Tags: COVID-19 Business Source Type: news

Clopidogrel atop rivaroxaban and aspirin shows no added benefit for PAD
(American College of Cardiology) The results of VOYAGER PAD found that people with peripheral artery disease (PAD) who took the blood thinner rivaroxaban with aspirin after undergoing lower extremity revascularization -- a procedure to treat blocked arteries in the leg -- had a significant reduction in the risk of major adverse limb and cardiovascular events when compared with those receiving aspirin alone, according to a subgroup analysis from VOYAGER PAD presented at the American College of Cardiology's Annual Scientific Session Together with World Congress of Cardiology (ACC.20/WCC). (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - March 30, 2020 Category: International Medicine & Public Health Source Type: news

Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS Larger Absolute Rivaroxaban Benefit in Diabetes: COMPASS
The new vascular low dose of rivaroxaban has gotten off to a slow start, but these new subgroup results may stimulate use in patients with diabetes and stable coronary or peripheral artery disease.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - March 29, 2020 Category: Cardiology Tags: Cardiology News Source Type: news

Landmark Phase 3 VOYAGER PAD Study of XARELTO ® (rivaroxaban) Plus Aspirin Shows Significant Benefit in Patients with Symptomatic Peripheral Artery Disease (PAD) after Lower-Extremity Revascularization
RARITAN, NJ, March 28, 2020 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the VOYAGER PAD study met its primary efficacy and principal safety endpoints, demonstrating the XARELTO® (rivaroxaban) vascular dose (2.5 mg twice daily) plus aspirin (100 mg once daily) was superior to aspirin alone in reducing the risk of major adverse limb and cardiovascular (CV) events by 15 percent in patients with symptomatic peripheral artery disease (PAD) after lower-extremity revascularization, with similar rates of TIMI[1] major bleeding. VOYAGER PAD is the only study to show a significant benefi...
Source: Johnson and Johnson - March 28, 2020 Category: Pharmaceuticals Tags: Innovation Source Type: news